The breadth and titer of maternal HIV-1-specific heterologous neutralizing antibodies are not associated with a lower rate of mother-to-child transmission of HIV-1

Journal of Virology

Volumn 86, Issue 19, 2012, Pages 10540-10546

  Chaillon, Antoine ^a,b   Wack, Thierry ^c,d   Braibant, Martine ^a   Mandelbrot, Laurent ^c,e   Blanche, Stéphane ^e   Warszawski, Josiane ^c,d   Barin, Francis ^a,b  

^a UNIVERSITÉ DE TOURS   (France)

^b CHU BRETONNEAU   (France)

^c CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY;

ADULT; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CELL ASSAY; CELL LINE; CELL STRAIN TZM BL; CHILDBIRTH; CLADISTICS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MODEL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNITY; INFANT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VERTICAL TRANSMISSION; VIRUS CLASSIFICATION; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS STRAIN; VIRUS TRANSMISSION;

ADULT; ANTIBODIES, NEUTRALIZING; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; MATERNAL EXPOSURE; MOTHERS; NEUTRALIZATION TESTS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

CERCOPITHECINE HERPESVIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84869056806     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00518-12     Document Type: Article

References (41)

1. Baba TW, et al. 2000. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6:200-206.
2. Barin F, et al. 2004. Interclade neutralization and enhancement of human immunodeficiency virus type 1 identified by an assay using HeLa cells expressing both CD4 receptor and CXCR4/CCR5 coreceptors. J. Infect. Dis. 189:322-327.
3. Barin F, et al. 2006. Revisiting the role of neutralizing antibodies in mother-to-child transmission of HIV-1. J. Infect. Dis. 193:1504-1511.
4. Barin F, et al. 2006. Human immunodeficiency virus serotyping on dried serum spots as a screening tool for the surveillance of the AIDS epidemic. J. Med. Virol. 78(Suppl 1):S13-S18.
5. Blish CA, et al. 2008. Human immunodeficiency virus type 1 superinfection occurs despite relatively robust neutralizing antibody responses. J. Virol. 82:12094-12103.
6. Bongertz V, et al. 2001. Vertical HIV-1 transmission: importance of neutralizing antibody titer and specificity. Scand. J. Immunol. 53:302-309.
7. Brand D, et al. 2004. First identification of HIV-1 groups M and O dual infections in Europe. AIDS 18:2425-2428.
8. Burton DR, et al. 2011. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc. Natl. Acad. Sci. U. S. A. 108:11181-11186.
9. Dickover R, et al. 2006. Role of maternal autologous neutralizing antibody in selective perinatal transmission of human immunodeficiency virus type 1 escape variants. J. Virol. 80:6525-6533.
10. Doria-Rose NA, et al. 2009. Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J. Virol. 83:188-199.
11. Dreja H, et al. 2010. Neutralization activity in a geographically diverse East London cohort of human immunodeficiency virus type 1-infected patients: clade C infection results in a stronger and broader humoral immune response than clade B infection. J. Gen. Virol. 91:2794-2803.
12. Englund J, Glezen WP, Piedra PA. 1998. Maternal immunization against viral disease. Vaccine 16:1456-1463.
13. Ferrantelli F, et al. 2004. Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. J. Infect. Dis. 189:2167-2173.
14. Hengel RL, et al. 1998. Neutralizing antibody and perinatal transmission of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 14:475-481.
15. Hessell AJ, et al. 2009. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 5:e1000433. doi:10.1371/journal.ppat.1000433.
16. Hessell AJ, et al. 2009. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 15: 951-954.
17. John GC, et al. 2001. Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections. J. Infect. Dis. 183:206-212.
18. Kishko M, et al. 2011. Genotypic and functional properties of early infant HIV-1 envelopes. Retrovirology 8:67.
19. Lathey JL, et al. 1999. Lack of autologous neutralizing antibody to human immunodeficiency virus type 1 (HIV-1) and macrophage tropism are associated with mother-to-infant transmission. J. Infect. Dis. 180:344-350.
20. Lynch JB, et al. 2011. The breadth and potency of passively acquired human immunodeficiency virus type 1-specific neutralizing antibodies do not correlate with the risk of infant infection. J. Virol. 85:5252-5261.
21. Mascola JR, et al. 2000. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6:207-210.
22. Mascola JR, et al. 1999. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73:4009-4018.
23. Mofenson LM, et al. 1999. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. N. Engl. J. Med. 341:385-393.
24. Parren PW, et al. 2001. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75:8340-8347.
25. Piantadosi A, et al. 2009. Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J. Virol. 83:10269-10274.
26. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D. 1998. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J. Virol. 72:2855-2864.
27. Reiser J, et al. 1996. Transduction of non-dividing cells using pseudotypes defective high-titer HIV type 1 particles. Proc. Natl. Acad. Sci. U. S. A. 93:15266-15271.
28. Rodriguez SK, et al. 2007. Comparison of heterologous neutralizing antibody responses of human immunodeficiency virus type 1 (HIV-1)and HIV-2-infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infections. J. Virol. 81:5331-5338.
29. Russell ES, et al. 2011. The genetic bottleneck in vertical transmission of subtype C HIV-1 is not driven by selection of especially neutralizationresistant virus from the maternal viral population. J. Virol. 85:8253-8262.
30. Safrit JT, et al. 2004. Immunoprophylaxis to prevent mother-to-child transmission of HIV-1. J. Acquir. Immune Defic. Syndr. 35:169-177.
31. Samleerat T, et al. 2009. Maternal neutralizing antibodies against a CRF01_AE primary isolate are associated with a low rate of intrapartum HIV-1 transmission. Virology 387:388-394.
32. Sather DN, et al. 2009. Factors associated with the development of crossreactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 83:757-769.
33. Scarlatti G, et al. 1993. Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates. J. Infect. Dis. 168:207-210.
34. Seaman MS, et al. 2010. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 84: 1439-1452.
35. Simek MD, et al. 2009. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J. Virol. 83:7337-7348.
36. Thenin S, et al. 2012. Envelope glycoproteins of human immunodeficiency virus type 1 variants issued from mother-infant pairs display a wide spectrum of biological properties. Virology 426:12-21.
37. Tubiana R, et al. 2010. Factors associated with mother-to-child transmission of HIV-1 despite a maternal viral load <500 copies/ml at delivery: a case-control study nested in the French perinatal cohort (EPF-ANRS CO1). Clin. Infect. Dis. 50:585-596.
38. Warszawski J, et al. 2008. Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French perinatal cohort. AIDS 22:289-299.
39. Wei X, et al. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:1896-1905.
40. Wu X, et al. 2006. Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant. J. Virol. 80: 835-844.
41. Zhang H, et al. 2010. Functional properties of the HIV-1 subtype C envelope glycoprotein associated with mother-to-child transmission. Virology 400:164-174.